AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30421079 — intervention group
Group type: COMPARATOR
Intervention: Robotic demolitive resection (DR Group)
Number of subjects: 25
Study 27914870 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitation alone (Agi)
Number of subjects: 272
Study 27914870 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggression alone
Number of subjects: 272
Study 27914870 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejection of care alone
Number of subjects: 272
Study 27914870 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitation and aggression (Agi+Aggr)
Number of subjects: 272
Study 27914870 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitation and rejection (Agi+Rej)
Number of subjects: 272
Study 27914870 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggression and rejection
Number of subjects: 272
Study 27914870 — intervention group
Group type: EXPERIMENTAL
Intervention: All three behaviors (Agi, Aggr, Rej)
Number of subjects: 272
Study 27914870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 272
Study 27914870 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver frustration
Number of subjects: 272
Study 27914870 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater cognitive impairment
Number of subjects: 272
Study 27914870 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater caregiver frustration
Number of subjects: 272
Study 27163418 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive-end expiratory pressure of 5 cm H2O (Group A, n=32)
Number of subjects: 78
Study 27163418 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive-end expiratory pressure of 8 cm H2O (Group B, n=26)
Number of subjects: 78
Study 27163418 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive-end expiratory pressure of 10 cm H2O (Group C, n=20)
Number of subjects: 78
Study 23703602 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 times/week abdominal meridian massage with aroma oils (AMMAO)
Number of subjects: 33
Study 23703602 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 times/week abdominal meridian massage with aroma oils (AMMAO)
Number of subjects: 33
Study 21296544 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures (Vicryl Plus)
Number of subjects: 241
Study 21296544 — intervention group
Group type: COMPARATOR
Intervention: Conventional Vicryl sutures
Number of subjects: 241
Study 19861543 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0-g bovine lactoferrin (bLF) daily for 12 months
Number of subjects: 104
Study 19861543 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-g bovine lactoferrin (bLF) daily for 12 months
Number of subjects: 104
Study 19861543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 16518959 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF) in combination with lopinavir/ritonavir, efavirenz, lamivudine, and tenofovir
Number of subjects: 16
Study 16518959 — intervention group
Group type: COMPARATOR
Intervention: Control group (no enfuvirtide) with the same four-drug regimen
Number of subjects: 16
Study 16518959 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF)
Number of subjects: 16
Study 16518959 — intervention group
Group type: COMPARATOR
Intervention: Control group (no enfuvirtide)
Number of subjects: 16
Study 15233288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node identification using lymphoscintigraphy and handheld gamma probe
Number of subjects: 11
Study 15233288 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathology of sentinel lymph nodes
Number of subjects: 11
Study 11506518 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous blood transfusion
Number of subjects: 128
Study 11506518 — intervention group
Group type: COMPARATOR
Intervention: No transfusion (Control)
Number of subjects: 128
Study 9407455 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 (6 g/day) concurrent with low protein diet (LPD)
Number of subjects: 26
Study 9407455 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (LPD) alone
Number of subjects: 26
Study 8508355 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with vincristine (VCR)
Number of subjects: 252
Study 8508355 — intervention group
Group type: COMPARATOR
Intervention: Induction therapy without vincristine (VCR)
Number of subjects: 252
Study 8508355 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 courses of maintenance‐intensification therapy
Number of subjects: 252
Study 8508355 — intervention group
Group type: COMPARATOR
Intervention: 4 courses of maintenance‐intensification therapy
Number of subjects: 252
Study 8508355 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results for CR
Number of subjects: 252
Study 8508355 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 252
Study 3479420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg orally twice daily for 14 days
Number of subjects: 26
Study 3479420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg orally twice daily for 14 days
Number of subjects: 26
Study 3479420 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo) not explicitly mentioned
Number of subjects: 26
Study 29986120 — intervention group
Group type: EXPERIMENTAL
Intervention: My Guide (Smartphone application)
Number of subjects: 25
Study 28061361 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroauricular (RA) approach
Number of subjects: 30
Study 28061361 — intervention group
Group type: COMPARATOR
Intervention: Conventional transcervical approach
Number of subjects: 30
Study 28061361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 30
Study 25616042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) at doses of 200-400 mg/kg
Number of subjects: 0
Study 25616042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) at doses of 600-800 mg/kg
Number of subjects: 0
Study 25616042 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 24342552 — intervention group
Group type: COMPARATOR
Intervention: OT only
Number of subjects: 18
Study 24342552 — intervention group
Group type: EXPERIMENTAL
Intervention: MP + OT
Number of subjects: 18
Study 24342552 — intervention group
Group type: EXPERIMENTAL
Intervention: OT only and MP + OT
Number of subjects: 18
Study 22119451 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion dysregulation
Number of subjects: 172
Study 22119451 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress tolerance
Number of subjects: 172
Study 22119451 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between emotion dysregulation and distress tolerance
Number of subjects: 172
Study 19110359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 404
Study 19110359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 17295082 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam irradiation (EBI) plus antiplatelet therapy
Number of subjects: 60
Study 17295082 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet therapy alone
Number of subjects: 60
Study 15170163 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood stem cells (BSC)
Number of subjects: 61
Study 15170163 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow (BM)
Number of subjects: 61
Study 15170163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential skin biopsies
Number of subjects: 61
Study 15170163 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected skin immunohistochemistry
Number of subjects: 61
Study 15170163 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal skin biopsies before GVHD outbreak
Number of subjects: 61
Study 11585352 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ibandronate 2.5 mg daily (n = 81)
Number of subjects: 240
Study 11585352 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ibandronate 20 mg every other day for the first 24 days (n = 78)
Number of subjects: 240
Study 11585352 — intervention group
Group type: COMPARATOR
Intervention: Continuous ibandronate (after crossover, n = 37)
Number of subjects: 240
Study 11585352 — intervention group
Group type: COMPARATOR
Intervention: Intermittent ibandronate (after crossover, n = 35)
Number of subjects: 240
Study 11585352 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (continuous and intermittent)
Number of subjects: 240
Study 10447226 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (NNS)
Number of subjects: 157
Study 7796795 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 10 mg
Number of subjects: 30
Study 7796795 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 30
Study 7796795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2496789 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 60 mg orally every four hours for 21 days
Number of subjects: 554
Study 2496789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study 723760 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate (2 X 1 g)
Number of subjects: 72
Study 723760 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (3 X 150 mg)
Number of subjects: 72
Study 723760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 29725824 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention spread with 2.0 g/day plant sterols and 1.0 g/day EPA+DHA from fish oil
Number of subjects: 260
Study 29725824 — intervention group
Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 260
Study 28529330 — intervention group
Group type: EXPERIMENTAL
Intervention: High MC-SFA
Number of subjects: 12
Study 28529330 — intervention group
Group type: COMPARATOR
Intervention: Low MC-SFA
Number of subjects: 12
Study 25123295 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) with prednisone
Number of subjects: 20
Study 25123295 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone (placebo)
Number of subjects: 20
Study 25127179 — intervention group
Group type: EXPERIMENTAL
Intervention: iACT (Internet-based ACT program)
Number of subjects: 0
Study 25127179 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face ACT treatment
Number of subjects: 0
Study 22376210 — intervention group
Group type: EXPERIMENTAL
Intervention: Test gel (anesthetic gel)
Number of subjects: 30
Study 22376210 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study 22376210 — intervention group
Group type: EXPERIMENTAL
Intervention: Test gel
Number of subjects: 30
Study 18636272 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional words
Number of subjects: 0
Study 18636272 — intervention group
Group type: EXPERIMENTAL
Intervention: High state anxiety
Number of subjects: 0
Study 18636272 — intervention group
Group type: COMPARATOR
Intervention: Neutral words
Number of subjects: 0
Study 17495015 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted-dose azathioprine therapy (adjusted to maintain 6-TGN concentrations between 250 and 400 pmol/8 x 10(8) erythrocytes)
Number of subjects: 71
Study 17495015 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose azathioprine therapy (2.5 mg/kg/day)
Number of subjects: 71
Study 17495015 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted-dose azathioprine therapy
Number of subjects: 71
Study 17495015 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose azathioprine therapy
Number of subjects: 71
Study 15121553 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Abdominal Hysterectomy (TAH)
Number of subjects: 120
Study 15121553 — intervention group
Group type: COMPARATOR
Intervention: Supracervical Hysterectomy (SCH)
Number of subjects: 120
Study 15121553 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline body mass index ≥ 35 kg/m²
Number of subjects: 120
Study 15121553 — intervention group
Group type: COMPARATOR
Intervention: Baseline body mass index < 35 kg/m²
Number of subjects: 120
Study 15121553 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy bleeding
Number of subjects: 120
Study 15121553 — intervention group
Group type: COMPARATOR
Intervention: No heavy bleeding
Number of subjects: 120
Study 11231772 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol and fluorometholone (group B)
Number of subjects: 0
Study 11231772 — intervention group
Group type: COMPARATOR
Intervention: PV and fluorometholone (group D)
Number of subjects: 0
Study 11231772 — intervention group
Group type: EXPERIMENTAL
Intervention: NPV and fluorometholone (group F)
Number of subjects: 0
Study 11231772 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups receiving diclofenac (groups A, C, E)
Number of subjects: 0
Study 11231772 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (0.5%)
Number of subjects: 0
Study 11231772 — intervention group
Group type: COMPARATOR
Intervention: PV or NPV (control groups)
Number of subjects: 0
Study 9754465 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate hemodialysis (AHD)
Number of subjects: 33
Study 8313125 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral IVN system with fine-bore silicone catheter and lipid-based nutrient solutions
Number of subjects: 46
Study 8313125 — intervention group
Group type: COMPARATOR
Intervention: Central IVN system with conventional glucose-based nutrient regimen and single-lumen central venous catheter
Number of subjects: 46
Study 8313125 — intervention group
Group type: COMPARATOR
Intervention: Comparison of complication-free system function over time between peripheral and central IVN
Number of subjects: 46
Study 2478330 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III/low-dose heparin (ATIII/LDH) regimen (3000 units loading dose followed by 2000 units daily and 5000 units of LDH twice daily)
Number of subjects: 42
Study 2478330 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight dextran (LMWD) (10 ml/kg x 12 hours loading dose followed by 7 ml/kg x 24 hours maintenance dose)
Number of subjects: 42
Study 2478330 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ATIII/LDH and LMWD)
Number of subjects: 42
Study 2478330 — intervention group
Group type: EXPERIMENTAL
Intervention: ATIII/LDH group
Number of subjects: 42
Study 786311 — intervention group
Group type: EXPERIMENTAL
Intervention: WA 335 (3 X 1 mg/die)
Number of subjects: 116
Study 786311 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (3 X 50 mg/die)
Number of subjects: 116
Study 29790196 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg)
Number of subjects: 57
Study 29790196 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 57
Study 28235726 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT plus AC (adjuvant cisplatin 80 mg/m2 and fluorouracil 800 mg/m2/d for 120 h every 4 weeks for three cycles)
Number of subjects: 508
Study 28235726 — intervention group
Group type: COMPARATOR
Intervention: CCRT only
Number of subjects: 508
Study 28235726 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT plus AC
Number of subjects: 508
Study 25920942 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke support service (outreach work, informational events, training sessions, online portal, written patient information)
Number of subjects: 265
Study 25920942 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke support service
Number of subjects: 265
Study 25920942 — intervention group
Group type: COMPARATOR
Intervention: Optimized standard care (written patient information)
Number of subjects: 265
Study 23228500 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5% H₂O₂ high‐adhesion whitening strip for 2h, once a day, for 8 days
Number of subjects: 29
Study 23228500 — intervention group
Group type: COMPARATOR
Intervention: 10% H₂O₂ whitening strip for 30 min, once a day, for 8 days
Number of subjects: 29
Study 23228500 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5% H₂O₂ high‐adhesion whitening strip
Number of subjects: 29
Study 23228500 — intervention group
Group type: COMPARATOR
Intervention: 10% H₂O₂ whitening strip
Number of subjects: 29
Study 22012289 — intervention group
Group type: EXPERIMENTAL
Intervention: II and IH nerve block with 10 mL of 0.75% ropivacaine and surgical wound infiltration with 10 mL of 0.75% ropivacaine
Number of subjects: 34
Study 22012289 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia with 15 mg hyperbaric 0.5% bupivacaine (Control Group)
Number of subjects: 34
Study 19198920 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 50
Study 19198920 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 50
Study 17403400 — intervention group
Group type: EXPERIMENTAL
Intervention: laxative (magnesium oxide + disodium phosphate)
Number of subjects: 53
Study 17403400 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 53
Study 15576019 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 x 10(6) IU of albumin-free recombinant streptokinase (rSK) in a one-hour intravenous infusion
Number of subjects: 25
Study 11171896 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg + prednisone
Number of subjects: 36
Study 11171896 — intervention group
Group type: COMPARATOR
Intervention: Placebo + prednisone
Number of subjects: 36
Study 9609895 — intervention group
Group type: EXPERIMENTAL
Intervention: Perflenapent emulsion (0.05 mL/kg)
Number of subjects: 151
Study 9609895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 7809568 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 12
Study 7809568 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 12
Study 7809568 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 12
Study 7809568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3406619 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive training with non-linear resistance (Group 1, n = 3)
Number of subjects: 5
Study 3406619 — intervention group
Group type: COMPARATOR
Intervention: Placebo training (Group 2, n = 2)
Number of subjects: 5
Study 31123001 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised antiplatelet therapy based on pharmacogenetic information and clinical features (pharmacogenetic group)
Number of subjects: 2382
Study 31123001 — intervention group
Group type: COMPARATOR
Intervention: Standard care based only on clinical features (standard group)
Number of subjects: 2382
Study 29970404 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-DBS
Number of subjects: 13
Study 29970404 — intervention group
Group type: COMPARATOR
Intervention: VIM-DBS
Number of subjects: 13
Study 27573427 — intervention group
Group type: EXPERIMENTAL
Intervention: Good QLQ‐C30 PF (score > 66.7%)
Number of subjects: 300
Study 27573427 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor QLQ‐C30 PF (score ≤ 66.7%)
Number of subjects: 300
Study 27573427 — intervention group
Group type: EXPERIMENTAL
Intervention: Good QLQ‐C30 PF
Number of subjects: 300
Study 27573427 — intervention group
Group type: COMPARATOR
Intervention: WHO PS
Number of subjects: 300
Study 24618231 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated ambient coarse particles (CAP; 76.2 ± 51.5 μg/m(3))
Number of subjects: 32
Study 24618231 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 32
Study 22795976 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac 0.5%
Number of subjects: 162
Study 22795976 — intervention group
Group type: EXPERIMENTAL
Intervention: nepafenac 0.1%
Number of subjects: 162
Study 22795976 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 162
Study 22795976 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac 0.5% and nepafenac 0.1%
Number of subjects: 162
Study 19093773 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous tumor cell-derived vaccines
Number of subjects: 0
Study 19093773 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic tumor cell-derived vaccines
Number of subjects: 0
Study 18192950 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive agents (inotropes and pressor agents)
Number of subjects: 0
Study 18192950 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilators
Number of subjects: 0
Study 18192950 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 0
Study 15167885 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Total Parenteral Nutrition (ETPN)
Number of subjects: 32
Study 15167885 — intervention group
Group type: COMPARATOR
Intervention: Late Total Parenteral Nutrition (LTPN)
Number of subjects: 32
Study 11669169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA) 3 mg/kg/day
Number of subjects: 99
Study 11669169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) 2,000 mg/day
Number of subjects: 99
Study 9676479 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback
Number of subjects: 8
Study 9676479 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative feedback
Number of subjects: 8
Study 9676479 — intervention group
Group type: COMPARATOR
Intervention: Control feedback
Number of subjects: 8
Study 7988307 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved glycemic control in poorly controlled NIDDM patients (54 patients)
Number of subjects: 210
Study 7988307 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients with HbA1c < 6.0% (62 patients)
Number of subjects: 210
Study 7988307 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients with HbA1c between 6.0 and 8.0% (75 patients)
Number of subjects: 210
Study 7988307 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients with HbA1c >= 8.0% (73 patients)
Number of subjects: 210
Study 7988307 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (46 subjects)
Number of subjects: 210
Study 7988307 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved glycemic control
Number of subjects: 210
Study 2847578 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium aerosol (2 inhalations; 2 mg/inhalation)
Number of subjects: 12
Study 2847578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31257987 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate imputation by treatment group
Number of subjects: 0